|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 315.30 CHF | -0.76% |
|
+0.64% | +23.41% |
| 07:05am | Roche Says Lymphoma Treatment Lunsumio Might Be Effective Earlier | DJ |
| 06:53am | European Commission Approves Roche Lupus Nephritis Treatment | DJ |
| Capitalization | 272B 337B 290B 253B 466B 30,290B 507B 3,151B 1,225B 14,357B 1,265B 1,238B 52,897B | P/E ratio 2025 * |
18.4x | P/E ratio 2026 * | 16.8x |
|---|---|---|---|---|---|
| Enterprise value | 285B 354B 304B 266B 489B 31,771B 532B 3,305B 1,285B 15,059B 1,327B 1,299B 55,484B | EV / Sales 2025 * |
4.63x | EV / Sales 2026 * | 4.43x |
| Free-Float |
87.84% | Yield 2025 * |
3.11% | Yield 2026 * | 3.17% |
Last Transcript: Roche Holding AG
| 1 day | -0.52% | ||
| 1 week | +0.64% | ||
| Current month | +2.57% | ||
| 1 month | +13.05% | ||
| 3 months | +16.91% | ||
| 6 months | +16.86% | ||
| Current year | +23.41% |
| 1 week | 308.6 |  | 319 |
| 1 month | 272.2 | | 319 |
| Current year | 231.9 | | 319 |
| 1 year | 231.9 | | 319 |
| 3 years | 212.9 | | 319 |
| 5 years | 212.9 | | 404.2 |
| 10 years | 206.35 | | 404.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 50 | 14/03/2023 | |
Alan Hippe
DFI | Director of Finance/CFO | 58 | 05/06/2011 |
Wafaa Mamilli
CTO | Chief Tech/Sci/R&D Officer | 58 | 09/02/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
André Hoffmann
BRD | Director/Board Member | 67 | 31/12/1995 |
Severin Schwan
CHM | Chairman | 58 | 14/03/2023 |
| Director/Board Member | 72 | 02/03/2015 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 9.03% | 121 M€ | -.--% | - |
| 8.46% | 26 M€ | +11.55% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.76% | +0.64% | +22.59% | +3.51% | 336B | |
| -0.29% | -4.78% | +23.96% | +175.95% | 893B | |
| +0.31% | -1.60% | +35.11% | +15.02% | 486B | |
| -0.25% | -0.86% | +25.98% | +36.42% | 394B | |
| +0.10% | -1.51% | +27.00% | +19.71% | 280B | |
| +0.17% | +0.58% | +19.51% | +24.96% | 253B | |
| -2.48% | -4.50% | -7.04% | -11.30% | 246B | |
| +0.07% | -2.56% | -61.75% | -35.08% | 207B | |
| -1.37% | -6.25% | +14.25% | +13.83% | 173B | |
| -1.71% | -3.56% | +31.91% | +35.84% | 150B | |
| Average | -0.61% | -2.03% | +13.15% | +27.89% | 341.87B | |
| Weighted average by Cap. | -0.44% | -2.41% | +18.01% | +55.46% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 61.58B 76.4B 65.64B 57.38B 106B 6,865B 115B 714B 278B 3,254B 287B 281B 11,988B | 63.14B 78.33B 67.3B 58.83B 108B 7,038B 118B 732B 285B 3,336B 294B 288B 12,291B |
| Net income | 13.23B 16.41B 14.1B 12.33B 22.7B 1,475B 24.67B 153B 59.62B 699B 61.58B 60.28B 2,575B | 14.64B 18.16B 15.6B 13.64B 25.11B 1,631B 27.29B 170B 65.97B 773B 68.14B 66.69B 2,849B |
| Net Debt | 13.29B 16.49B 14.17B 12.38B 22.81B 1,481B 24.78B 154B 59.9B 702B 61.87B 60.56B 2,587B | 8.15B 10.12B 8.69B 7.6B 13.99B 909B 15.21B 94.55B 36.75B 431B 37.96B 37.15B 1,587B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/12/25 | 315.30 CHF | -0.76% | 806,054 |
| 08/12/25 | 317.70 CHF | +2.19% | 1,032,888 |
| 05/12/25 | 310.90 CHF | +0.26% | 937,693 |
| 04/12/25 | 310.10 CHF | -1.18% | 1,018,755 |
| 03/12/25 | 313.80 CHF | +0.16% | 1,192,175 |
Delayed Quote Swiss Exchange, December 09, 2025 at 04:31 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ROG Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition